Results 151 to 160 of about 34,140,631 (244)

Male Sexual and Reproductive Health in Diabetes and Obesity Pharmacotherapy: A Source‐Triangulated Counseling Map

Andrology, EarlyView.
ABSTRACT Background Drugs used for diabetes and obesity increasingly shape male sexual and reproductive counseling, but clinical studies, trial registrations, regulatory labels, and patents answer different questions. Objectives The objective is to map these sources and define what each can support when counseling men receiving metabolic drugs ...
Marek Broul, Michal Dubský, Aneta Hujová, Michaela Liegertová   +3 more
wiley   +1 more source

Assessing the impact of pharmacist-led interventions on glucagon-like peptide 1 receptor agonist access and treatment outcomes. [PDF]

J Manag Care Spec Pharm
Huddleston H, Martinez J, Cook J, Trapp M, Chen NC, Schwander K, Moss S, Palkimas S.   +7 more
europepmc   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

Effects of the glucagon-like peptide-1 receptor agonist PEG-Loxe on diabetic osteoporosis: A mechanistic study. [PDF]

Mol Metab
Zhang L, Hu J, Huang C, Gao X, Pang D, Duan L.   +5 more
europepmc   +1 more source

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P. Toft‐Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi, Christian Torp‐Pedersen   +9 more
wiley   +1 more source

Orforglipron, a Small-Molecule Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA), Has Neuroprotective and Anti-Inflammatory Effects. [PDF]

Cells
Li Y, Glotfelty EJ, Parekh P, Batsaikhan B, Luo W, Jackson SN, Harvey BK, Greig NH.   +7 more
europepmc   +1 more source

Compartmentalisation in cAMP signalling: A phase separation perspective

British Journal of Pharmacology, EarlyView.
Cells rely on precise spatiotemporal control of signalling pathways to ensure functional specificity. The compartmentalisation of cyclic AMP (cAMP) and protein kinase A (PKA) signalling enables distinct cellular responses within a crowded cytoplasmic space.
Milda Folkmanaite, Manuela Zaccolo
wiley   +1 more source

Patients With Ileal Pouch-Anal Anastomosis Have Decreased Bowel Frequency on Glucagon-Like Peptide-1 Receptor Agonist Therapy. [PDF]

Clin Transl Gastroenterol
Chaudhry E, Kakadiya P, Vaughn H, Gray S, Hansen JJ, Haydek JP, Jain A, Long MD, Herfarth HH, Barnes EL.   +9 more
europepmc   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonist-based regimens compared with metformin-based regimens for preventing cardiovascular disease in adults with type 2 diabetes mellitus. [PDF]

Cochrane Database Syst Rev
Ahmed S, McCollin SP, Martí-Carvajal A, Akus M, Baron DW, Abdul Razzaq S, Scudder P, Honigsberg EJ, Nasir S, Peng K, Jahanfar S.   +10 more
europepmc   +1 more source